Researchers from China Medical University (Taiwan) and affiliated organizations have published results from a study that aimed to identify generic variants within the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway that could represent novel biomarkers in patients with prostate cancer.
The activation of PERK signaling triggers angiogenesis, migration and dissemination of cancer cells, and for that reason, the therapeutic blockade of the PERK pathway is a target to watch in cancer therapy. Researchers from Chongqing Medical University reported on the preclinical efficacy and molecular mechanism of CCT-020312, a selective PERK activator, in prostate cancer models.
Researchers from Renmin Hospital of Wuhan University have published results from their work that aimed to assess the role of exonuclease 1 (EXO1) in the progression of prostate cancer (PCa). A series of bioinformatic analyses revealed that EXO1 expression was higher in PCa tissue compared to normal tissue, and that high EXO1 expression predicted poor prognosis in PCa patients.
The Cleveland Clinic Foundation has described 3-β-hydroxysteroid dehydrogenase/δ5-->4-isomerase type 1 (3β-HSD I) inhibitors reported to be useful for the treatment of cancer.
Veracyte Inc. revealed plans to buy C2i Genomics Inc. at the J.P. Morgan Health Care Conference in San Francisco on Jan. 8, a move that will significantly expand its portfolio of cancer diagnostic and monitoring assays. The terms include $70 million in Veracyte shares to be paid at closing plus an addition $25 million payable in cash or Veracyte shares over the next two years if C2i achieves certain performance milestones.
Researchers at Albert-Ludwigs-Universität Freiburg and Deutsches Krebsforschungszentrum (DKFZ) have disclosed drug conjugates comprising fluorescent-labeled dye covalently linked to a radionuclide and a ligand targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) acting as positron-emission tomography (PET) and fluorescent imaging agents for diagnosis and treatment of prostate cancer.
Using minimally invasive focal therapies to treat prostate cancer are much more cost-effective and can improve patients’ quality of life compared to surgery or radiotherapy, according to a study published in the Journal of Medical Economics.
